PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 133 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2015. The put-call ratio across all filers is 1.52 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $736,000 | -26.2% | 193,584 | -1.2% | 0.00% | 0.0% |
| Q4 2019 | $997,000 | +41.4% | 195,884 | +40.4% | 0.00% | 0.0% |
| Q3 2019 | $705,000 | -3.0% | 139,500 | +18.3% | 0.00% | 0.0% |
| Q2 2019 | $727,000 | +21.2% | 117,900 | -8.9% | 0.00% | 0.0% |
| Q1 2019 | $600,000 | +10.5% | 129,400 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $543,000 | -40.0% | 129,400 | -10.4% | 0.00% | 0.0% |
| Q3 2018 | $905,000 | -20.1% | 144,415 | +2.6% | 0.00% | -50.0% |
| Q2 2018 | $1,132,000 | -11.9% | 140,800 | -18.2% | 0.00% | 0.0% |
| Q1 2018 | $1,285,000 | +25.4% | 172,200 | 0.0% | 0.00% | +100.0% |
| Q4 2017 | $1,025,000 | -19.1% | 172,200 | 0.0% | 0.00% | -50.0% |
| Q3 2017 | $1,267,000 | +8.4% | 172,200 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,169,000 | -28.1% | 172,200 | 0.0% | 0.00% | -33.3% |
| Q1 2017 | $1,626,000 | +4.7% | 172,200 | -4.2% | 0.00% | 0.0% |
| Q4 2016 | $1,553,000 | +29.8% | 179,700 | -4.9% | 0.00% | +50.0% |
| Q3 2016 | $1,196,000 | +40.4% | 188,900 | -6.4% | 0.00% | +100.0% |
| Q2 2016 | $852,000 | -6.1% | 201,800 | -3.0% | 0.00% | 0.0% |
| Q1 2016 | $907,000 | -32.9% | 208,100 | -5.7% | 0.00% | -50.0% |
| Q4 2015 | $1,352,000 | +7.1% | 220,600 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $1,262,000 | -23.3% | 220,600 | 0.0% | 0.00% | 0.0% |
| Q2 2015 | $1,646,000 | -11.8% | 220,600 | -26.6% | 0.00% | -33.3% |
| Q1 2015 | $1,867,000 | 0.0% | 300,642 | 0.0% | 0.00% | 0.0% |
| Q4 2014 | $1,867,000 | +19.7% | 300,642 | 0.0% | 0.00% | +50.0% |
| Q3 2014 | $1,560,000 | +24.5% | 300,642 | +3.4% | 0.00% | 0.0% |
| Q2 2014 | $1,253,000 | +10.6% | 290,646 | 0.0% | 0.00% | 0.0% |
| Q1 2014 | $1,133,000 | -26.5% | 290,646 | +7.2% | 0.00% | 0.0% |
| Q4 2013 | $1,542,000 | +37.8% | 271,062 | +21.8% | 0.00% | 0.0% |
| Q3 2013 | $1,119,000 | +12.8% | 222,515 | 0.0% | 0.00% | 0.0% |
| Q2 2013 | $992,000 | – | 222,515 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |